National Vision (EYE)
(Delayed Data from NSDQ)
$15.09 USD
+0.45 (3.07%)
Updated May 31, 2024 04:00 PM ET
After-Market: $15.11 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.09 USD
+0.45 (3.07%)
Updated May 31, 2024 04:00 PM ET
After-Market: $15.11 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Zacks News
Cooper Companies' (COO) CooperVision Gains Momentum Globally
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.
National Vision (EYE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Q3 Earnings Match Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 0.00% and 2.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q4 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q4 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.
Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is strongly placed to gain from the ongoing trend of digitalization in the global dental market.
4 Toxic Stocks to Discard or Sell Short for Solid Gains
by Zacks Equity Research
Overblown toxic stocks are usually vulnerable to outside shocks and loaded with a high level of debt.